Recognizing Excellence: Quinton Receives Frost & Sullivan Market Engineering Leadership Award.

Business Editors, Health/Medical Writers

BOTHELL, Wash.--(BUSINESS WIRE)--Sept. 23, 2002

Quinton Cardiology Systems, Inc. (Nasdaq:QUIN), a global leader in advanced cardiology products, announced today that it has received Frost & Sullivan's Market Engineering Award for 2002.

Quinton has been developing innovative cardiology products since 1953. Although the company faces competition from industry giants such as GE Medical and Philips Medical Systems, Quinton is being recognized by Frost & Sullivan for successfully executing its new product platform strategy and for establishing a leadership position in cardiac stress testing, its flagship product line.

According to Frost & Sullivan, the Market Engineering Leadership Award is given to the company that has "exhibited market share leadership through the implementation of market engineering strategy. Quinton has displayed excellence in all areas of the Market Engineering process, including the identification of market challenges, drivers and restraints, as well as strategy development and methods of addressing these market dynamics. Furthermore, Quinton was noted for continually demonstrating solutions for monitoring market changes and for implementing superior market engineering strategies. By utilizing these strategies, the company has established itself as the market share leader in the cardiac stress market." Award recipients excel by substantially increasing one or more of the following: market share, revenue growth, profitability, or market and technology innovation.

Frost & Sullivan recognized Quinton for setting the highest industry standard with its Q-Stress Cardiac Stress Test System. According to Frost & Sullivan estimates, Quinton commands an industry leading 27 percent of the cardiac stress test market. The innovative Q-Stress is designed to fit today's evolving health care needs by integrating technology and practicality to deliver exceptional ease-of-use.

Quinton's success, according to Frost & Sullivan, lays primarily in its customer-oriented focus and innovative approach to product development. Quinton has been known for providing excellent customer support and services. The efforts to deliver higher quality products is expected to help Quinton further penetrate domestic as well as international markets, increase sales and ultimately increase its market share.

Quinton has gone through siginficant change recently, which is expected to further improve its competitive capability. The company's PC-based platform strategy is yielding positive results, with numerous products and software updates coming quickly over the last 18 months. In addition to Q-Stress, Quinton has introduced Q-Tel rms; a Cardiac Rehabilitation Management System; Q-Cath 4.7, an upgrade to its popular hemodynamic monitoring system; and Q-Track II, an advanced Holter Monitoring System. The company also successfully completed an Initial Public Offering of Common Stock in May 2002.

Quinton develops, manufactures, markets and services a family of diagnostic cardiology systems used in the diagnosis, treatment and rehabilitation of patients with cardiovascular disease. Quinton shares are quoted on the Nasdaq National Market under the trading symbol "QUIN".

This press release contains forward-looking statements relating to Quinton's anticipated growth, market penetration and increases in market share that involve a number of risks and uncertainties. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "intend," anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Actual results may vary significantly from the results expressed or implied in these statements. Factors that could cause or contribute to such varying results include, but are not limited to, reduced demand for our products, delays in our product development activities and commercial introduction of product enhancements and new products, changes in competitors' products or their pricing which may impair the market acceptance of our products or force us to lower our prices, our inability to establish or maintain distribution and similar arrangements with third parties that may be necessary to expand market penetration in our existing markets and enter into new markets, disruptions in third party supplies of certain components we use in our products, the impact of acquisitions and divestitures, and costs associated with ongoing litigation against a former supplier. These and other risks are more fully described under the caption "Risk Factors" included in our Prospectus as filed with the Securities and Exchange Commission by Quinton Cardiology Systems, Inc. Quinton undertakes no duty or obligation to update the information provided herein.